kinase inhibitor

illustration of venture capital investment funding

Incyte vets raise $102M to create better PARP, PI3K drugs

A group of familiar faces to Incyte watchers has broken off to create competitors to approved cancer drugs from AstraZeneca, GSK, Novartis and Pfizer.

Nick Paul Taylor Jan 24, 2024 8:38am

Roche’s breast cancer drug hits primary endpoint in phase 3

Dec 5, 2023 4:12am

BeiGene offers up $1.3B in biobucks for preclinical cancer drug

Nov 21, 2023 7:13am

Roche pays $70M for HER2 breast cancer brain metastases prospect

May 9, 2023 6:30am

Aditum finds twist on old idea, paying $10M for BTK inhibitor

Apr 28, 2023 6:11am

Gossamer halts work on BTK inhibitor after 2 patient deaths

Apr 4, 2023 4:30am